Add-on Diuretics in Acute Decompensated Heart Failure
ConditionAcute Decompensated Heart Failure
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorTanta University
About this trial
The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.
Eligibility criteria
Qualifiers
Male or female patients older than 18 years.
Hospital admission with clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography).
Disqualifiers
Type 1 diabetes.
Chronic kidney disease with estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m² or end-stage kidney failure with the need for chronic dialysis treatment.
A systolic blood pressure of less than 90 mmHg.
Cardiogenic shock.
Trial design
Treatments tested in this trial
- empagliflozin
- Acetazolamide
- metolazone
Treatment groups
66 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov